Antihypertensive prescribing patterns in non-dialysis dependent chronic kidney disease: Findings from the Salford Kidney Study

Table 6 Number of patients prescribed with each antihypertensive class at baseline and at the 12-mo follow-up

Antihypertensive class	Baseline, n = 22561	12-mo follow-up, n = 22561	P value1
Diuretic (thiazide and loop)	1131 (50.1)	1107 (49.1)	0.475
CCB (dihydropyridine)	905 (40.1)	930 (41.2)	0.449
CCB (non- dihydropyridine)	102 (4.5)	90 (4.0)	0.376
Beta blocker	783 (34.7)	767 (34.0)	0.616
Alpha blocker	544 (24.1)	558 (24.7)	0.628
Central agent	111 (4.9)	117 (5.2)	0.683
Vasodilator	19 (0.8)	15 (0.7)	0.491
RAS blocker	1416 (62.8)	1383 (61.3)	0.311
Dual RAS blockers	145 (6.4)	163 (7.2)	0.288
Spironolactone/eplerenone	84 (3.7)	73 (3.2)	0.372

¹Absolute number for frequencies (percentages). The P values were calculated by the χ² test.

CCB: Calcium channel blocker, RAS: Renin angiotensin system.